LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 67

Search options

  1. Article ; Online: CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.

    Rouanne, Mathieu / Arpaia, Nicholas / Marabelle, Aurélien

    European journal of cancer (Oxford, England : 1990)

    2021  Volume 151, Page(s) 245–248

    MeSH term(s) Chemokine CXCL13 ; Humans ; Immunotherapy ; Tertiary Lymphoid Structures ; Urinary Bladder Neoplasms/therapy
    Chemical Substances CXCL13 protein, human ; Chemokine CXCL13
    Language English
    Publishing date 2021-05-07
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2021.03.054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Comment on: Relationship between the expression of PD-1/PD-L1 and

    Girard, Antoine / Rouanne, Mathieu

    European journal of nuclear medicine and molecular imaging

    2019  Volume 46, Issue 6, Page(s) 1212–1213

    MeSH term(s) B7-H1 Antigen ; Fluorodeoxyglucose F18 ; Humans ; Positron-Emission Tomography ; Programmed Cell Death 1 Receptor ; Urinary Bladder Neoplasms
    Chemical Substances B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2019-03-01
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 8236-3
    ISSN 1619-7089 ; 0340-6997 ; 1619-7070
    ISSN (online) 1619-7089
    ISSN 0340-6997 ; 1619-7070
    DOI 10.1007/s00259-019-04296-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1227: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: From mucosal infection to successful cancer immunotherapy.

    Goubet, Anne-Gaëlle / Rouanne, Mathieu / Derosa, Lisa / Kroemer, Guido / Zitvogel, Laurence

    Nature reviews. Urology

    2023  Volume 20, Issue 11, Page(s) 682–700

    Abstract: The clinical management of advanced malignancies of the upper and lower urinary tract has been revolutionized with the advent of immune checkpoint blockers (ICBs). ICBs reinstate or bolster pre-existing immune responses while creating new T cell ... ...

    Abstract The clinical management of advanced malignancies of the upper and lower urinary tract has been revolutionized with the advent of immune checkpoint blockers (ICBs). ICBs reinstate or bolster pre-existing immune responses while creating new T cell specificities. Immunogenic cancers, which tend to benefit more from immunotherapy than cold tumours, harbour tumour-specific neoantigens, often associated with a high tumour mutational burden, as well as CD8
    MeSH term(s) Humans ; Immunotherapy ; Urinary Bladder Neoplasms/pathology ; Prognosis ; Urinary Bladder/pathology ; Antigens, Neoplasm ; Adjuvants, Immunologic/therapeutic use
    Chemical Substances Antigens, Neoplasm ; Adjuvants, Immunologic
    Language English
    Publishing date 2023-07-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2493737-X
    ISSN 1759-4820 ; 1759-4812
    ISSN (online) 1759-4820
    ISSN 1759-4812
    DOI 10.1038/s41585-023-00784-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6030: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.

    Chung, Rainjade / McKiernan, James / Arpaia, Nicholas / Marabelle, Aurélien / Rouanne, Mathieu

    European journal of cancer (Oxford, England : 1990)

    2023  Volume 187, Page(s) 58–64

    Abstract: Bacillus Calmette-Guerin (BCG) is a live attenuated Mycobacterium bovis strain, originally developed as a vaccine against tuberculosis. It is also the only bacterial cancer therapy approved by the US Food & Drug Administration for clinical use. BCG is ... ...

    Abstract Bacillus Calmette-Guerin (BCG) is a live attenuated Mycobacterium bovis strain, originally developed as a vaccine against tuberculosis. It is also the only bacterial cancer therapy approved by the US Food & Drug Administration for clinical use. BCG is delivered in the bladder, shortly after tumour resection, for patients with high-risk non-muscle invasive bladder cancer (NMIBC). Modulating mucosal immunity by exposing the urothelium to intravesical BCG has been the main therapeutic strategy for high-risk NMIBC over the last three decades. Thus, BCG provides a benchmark for the clinical development of bacteria-or other live attenuated pathogens-as cancer therapy. Currently, a myriad of immuno-oncology compounds is under clinical evaluation in BCG-unresponsive and BCG-naïve patients as an alternative therapy in the context of worldwide BCG shortages. For patients with non-metastatic muscle-invasive bladder cancer (MIBC), studies investigating neoadjuvant immunotherapy with either anti-PD-1/PD-L1 monoclonal antibodies in monotherapy or in combination with anti-CTLA-4 monoclonal antibodies have shown overall efficacy and acceptable safety profiles prior to radical cystectomy. Emerging clinical investigations are testing synergistic approaches by combining intravesical delivery of drugs with systemic immune checkpoint blockades in the neoadjuvant setting for patients with MIBC. Such novel strategy aims to prime a local anti-tumour immunity and reduce distant metastatic relapses by enhancing a systemic adaptive anti-tumour immune response. Here, we present and discuss some of the most promising clinical trials developing such novel therapeutic approaches.
    MeSH term(s) Humans ; BCG Vaccine/therapeutic use ; Neoadjuvant Therapy ; Immunity, Mucosal ; Neoplasm Recurrence, Local/drug therapy ; Adjuvants, Immunologic/therapeutic use ; Urinary Bladder Neoplasms/drug therapy ; Immunotherapy ; Drug Development ; Neoplasm Invasiveness
    Chemical Substances BCG Vaccine ; Adjuvants, Immunologic
    Language English
    Publishing date 2023-04-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2023.03.037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.

    Rouanne, Mathieu / Radulescu, Camélia / Adam, Julien / Allory, Yves

    World journal of urology

    2020  Volume 39, Issue 5, Page(s) 1345–1355

    Abstract: Purpose: While immunotherapy has become an increasingly attractive strategy in patients with urothelial bladder cancer, the need for a biomarker to identify patients whose cancer is the most likely to respond has never been more crucial. This review ... ...

    Abstract Purpose: While immunotherapy has become an increasingly attractive strategy in patients with urothelial bladder cancer, the need for a biomarker to identify patients whose cancer is the most likely to respond has never been more crucial. This review systematically evaluates evidence regarding PD-L1 as a predictive biomarker of response to anti-PD(L)1 monoclonal antibodies in patients with urothelial bladder carcinoma, and discusses its current limits in routine clinical practice.
    Methods: We performed a critical review of PubMed/Medline according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statement. Prospective clinical trials evaluating anti-PD(L)1 monoclonal antibodies in urothelial bladder carcinoma together with retrospective studies evaluating PD-L1 expression in patients with bladder cancer were included.
    Results: Evidence data related to PD-L1 as a predictive biomarker of response to immune checkpoint blockade monotherapy across clinical trials are detailed in this review. The different companion diagnostic assays, and the methods for PD-L1 scoring in urothelial bladder carcinoma are reported. Additionally, the issues related to the implementation of PD-L1 testing in clinical practice are discussed.
    Conclusions: PD-(L)1 monoclonal antibodies atezolizumab and pembrolizumab are restricted to patients with PD-L1 positive status in the first-line setting in patients with advanced or metastatic urothelial bladder carcinoma who are ineligible to cisplatin-based chemotherapy. Importantly, the use of anti-PD(L)1 mAb in the other clinical settings is not based on PD-L1 status, but rather on patients' clinical characteristics. Further identification of biomarkers with high negative predictive value will also be of utmost importance to identify patients who may not respond to such immunotherapies.
    MeSH term(s) B7-H1 Antigen/analysis ; Biomarkers, Tumor/analysis ; Carcinoma, Transitional Cell/chemistry ; Carcinoma, Transitional Cell/diagnosis ; Carcinoma, Transitional Cell/therapy ; Humans ; Urinary Bladder Neoplasms/chemistry ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/therapy
    Chemical Substances B7-H1 Antigen ; Biomarkers, Tumor ; CD274 protein, human
    Language English
    Publishing date 2020-11-03
    Publishing country Germany
    Document type Journal Article ; Systematic Review
    ZDB-ID 380333-8
    ISSN 1433-8726 ; 0724-4983
    ISSN (online) 1433-8726
    ISSN 0724-4983
    DOI 10.1007/s00345-020-03498-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1832: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination.

    Rouanne, Mathieu / Zitvogel, Laurence / Marabelle, Aurélien

    Cancer discovery

    2020  Volume 10, Issue 8, Page(s) 1097–1099

    Abstract: In this issue ... ...

    Abstract In this issue of
    MeSH term(s) Antibodies, Monoclonal ; B7-H1 Antigen ; CD8-Positive T-Lymphocytes ; Humans ; Interleukin-2/analogs & derivatives ; Neoplasms/drug therapy ; Nivolumab ; Plant Nectar ; Polyethylene Glycols
    Chemical Substances Antibodies, Monoclonal ; B7-H1 Antigen ; Interleukin-2 ; Plant Nectar ; Nivolumab (31YO63LBSN) ; Polyethylene Glycols (3WJQ0SDW1A) ; bempegaldesleukin (BNO1JG5MZC)
    Language English
    Publishing date 2020-08-12
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-20-0786
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Utility of Routine Preoperative

    Girard, Antoine / Vila Reyes, Helena / Dercle, Laurent / Rouanne, Mathieu

    The Journal of urology

    2021  Volume 206, Issue 1, Page(s) 169–170

    MeSH term(s) Cystectomy ; Fluorodeoxyglucose F18 ; Humans ; Lymphatic Metastasis ; Positron-Emission Tomography ; Tomography, X-Ray Computed
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2021-04-01
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1097/JU.0000000000001753
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.91: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 331: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: "Future role of [18F]-FDG PET/CT in patients with bladder cancer in the new era of neoadjuvant immunotherapy?"

    Girard, Antoine / Vila Reyes, Helena / Dercle, Laurent / Rouanne, Mathieu

    Urologic oncology

    2021  Volume 39, Issue 2, Page(s) 139–141

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Fluorodeoxyglucose F18 ; Glucose ; Humans ; Immunotherapy ; Lymph Nodes ; Muscles ; Neoadjuvant Therapy ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Urinary Bladder Neoplasms/diagnostic imaging ; Urinary Bladder Neoplasms/therapy
    Chemical Substances Antibodies, Monoclonal, Humanized ; Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; pembrolizumab (DPT0O3T46P) ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2021-01-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1336505-8
    ISSN 1873-2496 ; 1078-1439
    ISSN (online) 1873-2496
    ISSN 1078-1439
    DOI 10.1016/j.urolonc.2020.12.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4817: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals.

    Bonvalet, Mélodie / Danlos, François-Xavier / Champiat, Stéphane / Rouanne, Mathieu / Marabelle, Aurélien

    European journal of cancer (Oxford, England : 1990)

    2022  Volume 162, Page(s) 130–132

    MeSH term(s) Biology ; Drug Approval ; Drug Development ; Humans ; Immunotherapy ; Neoplasms/drug therapy ; Neoplasms/pathology
    Language English
    Publishing date 2022-01-01
    Publishing country England
    Document type Editorial
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2021.12.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Rationale for LDH-targeted cancer immunotherapy.

    Miholjcic, Tina B S / Halse, Heloise / Bonvalet, Mélodie / Bigorgne, Amélie / Rouanne, Mathieu / Dercle, Laurent / Shankar, Vishnu / Marabelle, Aurélien

    European journal of cancer (Oxford, England : 1990)

    2022  Volume 181, Page(s) 166–178

    Abstract: Immunotherapies have significantly improved the survival of patients in many cancers over the last decade. However, primary and secondary resistances are encountered in most patients. Unravelling resistance mechanisms to cancer immunotherapies is an area ...

    Abstract Immunotherapies have significantly improved the survival of patients in many cancers over the last decade. However, primary and secondary resistances are encountered in most patients. Unravelling resistance mechanisms to cancer immunotherapies is an area of active investigation. Elevated levels of circulating enzyme lactate dehydrogenase (LDH) have been historically considered in oncology as a marker of bad prognosis, usually attributed to elevated tumour burden and cancer metabolism. Recent evidence suggests that elevated LDH levels could be independent from tumour burden and contain a negative predictive value, which could help in guiding treatment strategies in immuno-oncology. In this review, we decipher the rationale supporting the potential of LDH-targeted therapeutic strategies to tackle the direct immunosuppressive effects of LDH on a wide range of immune cells, and enhance the survival of patients treated with cancer immunotherapies.
    MeSH term(s) Humans ; Immunotherapy ; L-Lactate Dehydrogenase/metabolism ; Neoplasms/metabolism ; Neoplasms/therapy ; Prognosis
    Chemical Substances L-Lactate Dehydrogenase (EC 1.1.1.27)
    Language English
    Publishing date 2022-12-14
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2022.11.032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top